Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Boehringer Ingelheim
Baxter
Moodys
Dow

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

QOLIANA Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which patents cover Qoliana, and when can generic versions of Qoliana launch?

Qoliana is a drug marketed by Sandoz Inc and is included in one NDA. There is one patent protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in QOLIANA is brimonidine tartrate. There are eleven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.

US ANDA Litigation and Generic Entry Outlook for Qoliana

  Start Trial

A generic version of QOLIANA was approved as brimonidine tartrate by BAUSCH AND LOMB on January 18th, 2020.

Summary for QOLIANA
International Patents:1
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 60
Patent Applications: 40
DailyMed Link:QOLIANA at DailyMed
Drug patent expirations by year for QOLIANA
Pharmacology for QOLIANA
Synonyms for QOLIANA
(4,5-Bihydro-1H-imidazol-2-yl)quinoxalin-6-amine L-tartrate
(5-Bromo-quinoxalin-6-yl)-(4,5-dihydro-1h-imidazol-2-yl)-amine L-tartrate
109826-56-4
359B465
4S9CL2DY2H
5-bromo-N-
5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine L-Tartrate
5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate
5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine; (2R,3R)-2,3-dihydroxybutanedioic acid
59803-98-4 (Parent)
59803-99-5
6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1)
6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-, (S-(R*,R*))-2,3-dihydroxybutanedioate (1:1)
70359-46-5
79570-19-7
A19740
AB0021226
AC1L1GYC
AC1Q59OR
ACT08633
AGN 190342-LF
AGN 190342LF
AGN-190342-LF
AK-68418
AKOS016845265
Alphagan
Alphagan (TN)
Alphagan-P
AN-12800
AS-18083
Brimonidine (tartrate)
Brimonidine D-tartarate
Brimonidine D-tartrate
Brimonidine L-Tartrate
brimonidine Purite
Brimonidine tartarate
BRIMONIDINE TARTRATE
brimonidine tartrate (1:1), (S-(R*,R*))-isomer
Brimonidine tartrate (JAN/USAN)
Brimonidine tartrate [USAN:JAN]
Brimonidine tartrate [USAN]
Brimonidine tartrateUK 14,304 tartrate
Brimonidinne tartrate
Brominide tartrate
C11H10BrN5.C4H6O6
CCG-221278
CS-4496
D02076
EBD23481
HMS3715P18
HY-B0659A
KS-00000K6V
LS-177484
MolPort-023-220-671
N-(5-bromoquinoxalin-6-yl)imidazolidin-2-imine;(2R,3R)-2,3-dihydroxybutanedioic acid
SCHEMBL265607
ST24046243
UK 14,304 (tartrate)
UK-14304-18
UNII-4S9CL2DY2H
W0014

US Patents and Regulatory Information for QOLIANA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz Inc QOLIANA brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 021764-001 May 22, 2006 AT RX No No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for QOLIANA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1631293 2014/041 Ireland   Start Trial PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221
1631293 300683 Netherlands   Start Trial PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293 C300683 Netherlands   Start Trial PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Merck
McKinsey
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.